Keloids – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Keloids Market Outlook
Thelansis’s “Keloids Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Keloids treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Keloids
Overview
Keloids,
which result from abnormal wound healing triggered by skin trauma or
inflammation, are influenced by both genetic and environmental factors. They
are more prevalent among individuals of African, Asian, and Hispanic descent.
Overactive fibroblasts, producing excessive collagen and growth factors, are
implicated in their pathogenesis, leading to the characteristic histologic
findings of keloidal collagen bundles and numerous fibroblasts. Clinically,
keloids manifest as firm, rubbery nodules extending beyond the initial injury
site, often accompanied by pain, itching, or burning. The differential
diagnosis includes hypertrophic scars, which are smaller and confined to the
injury area, and dermatofibroma, characterized by flesh-colored or hyperpigmented
papules or nodules. Due to the therapeutic challenges posed by keloids,
prevention plays a crucial role. For predisposed individuals, it is recommended
to avoid elective procedures, especially ear piercing and tattooing. Minimizing
wound tension and employing compression therapy with pressures of 15 to 45 mmHg
for over 23 hours daily for at least 6 months can help reduce keloid formation
and growth.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment